Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.

Abstract

BACKGROUND AND AIMS:

We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].

METHODS:

We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.

RESULTS:

Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.

CONCLUSIONS:

There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.

• Authors: Thomas Chateau, Stefanos Bonovas, Catherine Le Berre, Nicolas Mathieu, Silvio Danese, Laurent Peyrin-Biroulet
• Journal: Journal of Crohn's & colitis (J Crohns Colitis) Vol. 13 Issue 12 Pg. 1569-1577 (Dec 10 2019) ISSN: 1876-4479 [Electronic] England
• PMID: 31076751 (Publication Type: Journal Article, Systematic Review)
• Copyright: Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

Chemical References

• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• Integrins
• vedolizumab

Topics

• Antibodies, Monoclonal, Humanized (pharmacology)
• Arthritis (drug therapy, etiology)
• Cholangitis, Sclerosing (drug therapy, etiology)
• Gastrointestinal Agents (pharmacology)
• Humans
• Inflammatory Bowel Diseases (complications)
• Integrins (antagonists & inhibitors)
• Skin Diseases (drug therapy, etiology)
• Treatment Outcome